StockpollyBeta
Get App
Popularity #961
SPRY · NASDAQ · Biotechnology

ARS Pharmaceuticals (SPRY)

Maker of the first FDA-approved needle-free nasal spray for severe allergic reactions.

$4.24
vs last close−0.25 (−5.47%)

In millions of USD, except per-share figures

In millionsQ3 FY23Sep 2023Q4 FY23Dec 2023Q1 FY24Mar 2024Q2 FY24Jun 2024Q3 FY24Sep 2024Q4 FY24Dec 2024Q1 FY25Mar 2025Q2 FY25Jun 2025Q3 FY25Sep 2025Q4 FY25Dec 2025Q1 FY26Mar 2026Q2 FY26Jun 2026
Revenue000128781633282334
Cost of revenue3357044583613
Gross profit−3−3−5−628341124251621
157892435415878667782
Research & development335743343345
000919005475607278
General & administrative000919005400078
Other expenses1233−70323800300
Operating income−18−10−13−15−2247−37−48−53−41−60−61
33333333200−1
Interest income000000000022
Interest expense000000000022
Other non-operating income0−3−3−3−3−3−3−3−20−2−2
Income before tax−15−7−10−13−1950−34−45−51−41−61−62
Income tax expense000000000000
Net income from continuing operations−15−7−10−13−1950−34−45−51−41−61−62
Net income−15−7−10−13−1950−34−45−51−41−61−62
EPS, basic−$0.16−$0.07−$0.11−$0.13−$0.20$0.51−$0.35−$0.46−$0.52−$0.42−$0.61−$0.63
EPS, diluted−$0.16−$0.07−$0.11−$0.13−$0.20$0.51−$0.35−$0.46−$0.52−$0.42−$0.61−$0.63
Weighted average shares, basic969696979798989899999999
Weighted average shares, diluted969696979798989899999999
EBITDA−18−7−10−12−1950−34−45−49−41−58−59
Depreciation & amortization000000002000
EBIT−18−7−10−13−1950−34−45−51−41−58−60